Skip to content

Study · Not a test of the peptide alone · 2015

3 results

Ghrelin Is a Novel Regulator of GLP-1 Secretion.

Gagnon J, Baggio LL, Drucker DJ, Brubaker PL

Diabetes20 Nov 2014Cited by 80 (Europe PMC)

PMID25412624 (opens in a new tab)DOI10.2337/db14-1176 (opens in a new tab)PepBankPUB-25412624
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 01AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism

    In mice, D-Lys GHRP‑6 reduced plasma GLP-1 levels during oral glucose testing.

    In plain wordsIn mice, modified GHRP‑6 reduced blood GLP-1 levels.

    Peptide
    GHRP-6
    Outcome
    DecreasePlasma GLP-1
    Study

    mousen: not reported in source

    Oral glucose challenge
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    whereas the ghrelin receptor antagonist D-Lys GHRP-6 reduced plasma levels of GLP-1 and insulin and diminished oral glucose tolerance.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 02AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism

    In mice, D-Lys GHRP‑6 reduced plasma insulin levels during oral glucose testing.

    In plain wordsIn mice, modified GHRP‑6 reduced blood insulin levels.

    Peptide
    GHRP-6
    Outcome
    DecreasePlasma insulin
    Study

    mousen: not reported in source

    Oral glucose challenge
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    whereas the ghrelin receptor antagonist D-Lys GHRP-6 reduced plasma levels of GLP-1 and insulin and diminished oral glucose tolerance.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  3. 03AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism

    In mice, D-Lys GHRP‑6 diminished oral glucose tolerance.

    In plain wordsIn mice, modified GHRP‑6 worsened glucose tolerance.

    Peptide
    GHRP-6
    Outcome
    DecreaseOral glucose tolerance
    Study

    mousen: not reported in source

    Oral glucose challenge
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    whereas the ghrelin receptor antagonist D-Lys GHRP-6 reduced plasma levels of GLP-1 and insulin and diminished oral glucose tolerance.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.